Abstract 1285P
Background
The patient (pt) characteristics, risk factors, and treatment outcomes of LCINS remain poorly understood. We present data from a large UK-based bespoke LCINS clinical database.
Methods
We retrospectively collected data from electronic records and analysed outcomes of LCINS pts treated at Guy’s Cancer Centre, South East London, from 2010 until 2021.
Results
483 pts were included, which accounted for 7% of all lung cancer pts. Median age was 67 years (range 25-95), 68% of pts were female (versus 43% in smokers); 50% White, 22% Black, 16% Asian, 2% mixed race, and 10% unknown (versus 72%, 5%, 2%, 2%, 18% in smokers). 8% of pts had asthma, 2% previous tuberculosis, 1% COPD, 1% interstitial lung disease, while 7% had passive smoking and 5% known asbestos exposure. 49% were overweight. 21% of pts had a history of other cancers and 5% a first-degree family history of lung cancer. Most (64%) pts presented with stage IV disease, and 16%, 6%, and 15% with stage I, II, and III respectively. Most (80%) pts had adenocarcinoma, 9% squamous cell, and 4% small cell. 50% of pts had a driver genetic aberration, although genetic testing varied dependent on histological subtype and year of diagnosis. The commonest were EGFR, ALK, KRAS, and ROS1 aberrations found in 48%, 11%, 8%, and 5% of pts tested for each gene respectively. Out of the 174 (36%) pts with stage I-III disease, 57% had curative surgery, 39% radical (chemo)radiotherapy, and 22% adjuvant chemotherapy (CT). Of all 376 metastatic pts (64% de novo and 14% relapsed), 38% had brain metastases. A total of 81%, 45%, and 23% of metastatic pts had 1, 2, and 3 lines of systemic therapy respectively. In the 1st -line setting, 47% had a tyrosine kinase inhibitor (TKI), 40% CT, and 6% CT-immunotherapy (IO). Overall, 53% of the metastatic pts had a TKI, 52% CT, and 16% IO at any treatment line. The median overall survival was 9.2, 4.0, 3.3, and 1.4 years for stage I, II, III, and IV disease respectively.
Conclusions
LCINS spans all age groups and ethnic backgrounds. Most pts are female with limited respiratory comorbidities. Pts present with advanced adenocarcinoma with a high incidence of brain metastases and driver genetic aberrations. Strategies to improve earlier stage diagnosis in LCINS are urgently needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
EveryBreath Lung Cancer Support Group, Guy's Cancer Charity, National Institute for Health and Care Research.
Disclosure
C. Gousis: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Stocks/Shares: Mind Medicine, Kiniksa Pharmaceuticals; Non-Financial Interests, Personal, Training, Travel and accommodation: AstraZeneca. H. McGrath: Non-Financial Interests, Personal, Other, Conference registration support: Amgen. A. Bille: Financial Interests, Personal, Speaker, Consultant, Advisor: Intuitive Surgical, BD. S. Ghosh: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Chugai, MSD, AstraZeneca, Pfizer, Takeda, Roche. S. Gennatas: Financial Interests, Personal, Invited Speaker, Presentations to health professionals: Amgen; Financial Interests, Personal, Invited Speaker, Presentation to health care professionals: Chugai. J. Spicer: Financial Interests, Institutional, Advisory Board, Compensation to my employer for time providing advice: Lilly, AstraZeneca, BMS, GSK, RS Oncology; Financial Interests, Personal, Stocks/Shares, Co-founder: Epsilogen; Financial Interests, Institutional, Local PI, Reimbursement for treatment of patients in trial: Achilles, Genmab, Roche, Seattle Genetics, Trizell, BergenBio, MSD, Gilead; Financial Interests, Institutional, Coordinating PI, Reimbursement for treatment of patients in trial: Starpharma, BMS, IO Biotech, RS Oncology; Non-Financial Interests, Member of Board of Directors, National strategy board: Experimental Cancer Medicine Centres; Non-Financial Interests, Member of Board of Directors, Steering Committee: British Thoracic Oncology Group; Non-Financial Interests, Advisory Role, Advice on licensing decisions for MHRA: CHM Expet Advisory Group on Oncology & Haematology. A. Georgiou: Financial Interests, Personal, Speaker, Consultant, Advisor, Honoraria-Speaker: Amgen/Takeda; Financial Interests, Personal, Speaker, Consultant, Advisor, Honoraria-Speaker/Consultancy: Merck; Financial Interests, Personal, Speaker, Consultant, Advisor, Honoraria-Consultancy: AstraZeneca; Financial Interests, Personal, Other, Conference registration support: Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04